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1. Introduction
  Leishmaniasis is a widespread parasitic disease, reported 
from 98 countries of the world. So far, there is not any effective 
vaccine or drug to control this disease, or appropriate 
chemical method for definite fight against the vector available. 
The annual new cases of leishmaniasis are estimated to be 
one to two million cases. Leishmaniasis globally threatens 350 
millions of people throughout the world. Visceral leishmaniasis 
is responsible for 20 000 to 40 000 deaths annually[1-3].  
  Using the currently available treatment methods, it is 
not possible to treat cutaneous leishmaniasis completely. 
Moreover, the treatments are associated with the infection 
recurrence, secondary bacterial infections, high costs, 
and being opportunistic in immunocompromised people. 
Considering these facts and also the high prevalence rate of 
the disease and the disease distribution, evaluation of novel 
effective methods for prevention and treatment of cutaneous 
leishmaniasis is indicated[3,4].
  Some plasmids encoding exogenous cytokines (such as 
IL-6, IL-7, or IL-12) can potentially induce the cellular and 
humoral immune responses. Particularly when application of 
these plasmids is accompanied by DNA vaccines, they provide 
a robust method for enhancement or shift of the immune 
response against the antigen encoded by the DNA[5-7].
  IL-12 is involved in stimulation of adaptive and natural 
immune responses, and plays an important role in induction 
of the Th1 response and suppression of the Th2 response. 
This cytokine increases the cytotoxic activity and production 
of INF-毭 by dendritic cells (DCs). Moreover, IL-12 
enhances INF-毭 production and Th1 evolution through 
the signaling pathways increasing the STAT-4 activity. 
Therefore, the cytokines have been introduced as crucial 
inducers in evolution of T-helper subpopulations[8, 9].
  Studies have shown that IL-12 production is suppressed 
in contaminated macrophages. Promastigotes and 
amastigotes of different Leishmania strains suppress IL-
12 production in contaminated cells. IL-12 is produced 
by non-contaminated macrophages and dendritic cells 
that are not suppressed. The mechanism of suppression 
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is not thoroughly understood. In this respect, it is known 
that lipophosphoglycans involve in suppression of IL-12 
production. However, other molecules are also effective in 
the process. Binding of CR3 receptors would decrease IL-12 
production. Since Leishmania employs this receptor to enter 
the cell, inhibition of IL-12 production may be explained by 
this mechanism[10, 11].
  IL-22, which is also called interleukin-10-related T cell-
derived inducible factor (IL-TIF), is secreted by Th-17, 
natural killer cells, Th22 and T cells (Th1) immediately after 
activation of these cells by IL-4. Moreover, the cytokine 
is secreted by thymic and brain mast cells following their 
activation by Con-A. This is one of the few cytokines, 
which has been confirmed to be present in non-mammalian 
animals such as fish[12-16].
  It has been confirmed that cutaneous keratinocytes have 
receptors for IL-22. In the skin, IL-22 induces antimicrobial 
peptides, enhances the proliferation and inhibits the 
differentiation of keratinocytes, and plays a role in wound 
healing and innate immunity mechanisms. The role of IL-
22 in skin disorders such as atopic eczema and allergic 
contact dermatitis is unknown[17]. IL-22 produced by human 
NK cells inhibits growth of Mycobacterium tuberculosis 
by enhancing phagolysosomal fusion and activation of 
macrophages[18].
  In a previous study it was shown that resistance to human 
Kala-azar is related to levels of IL-22[19]. The present study 
was fulfilled to evaluate the effect of IL-22 administration 
solely and accompanied by the IL-12-encoding plasmid on 
cutaneous leishmaniasis caused by Leishmania major (L. 
major) in BALB/c mice.
2. Materials and methods 
2.1. Experimental  mice 
  Since BALB/c mice are susceptible to promastigotes of
L. major, we bought 60 white female inbred BALB/c mice 
at the age of eight weeks from the Razi Vaccine and Serum 
Research Institute (Hesarak, Karaj). The mice were kept 
under standard condition and received standard food and 
water. The mice were categorized according to the treatments 
they received. The sixty mice were divided into six groups, 
each including 10 mice. 
2.2. Recombinant plasmid pCAGGS-IL-12 
  Recombinant IL-12 plasmid containing a part of the gene 
expressing IL-12, which was constructed in the form of 
pCAGGS-IL-12, was kindly donated by Prof. Masanori 
Matsui (University of Tokyo, Japan).
  Primary and mass culture of the plasmid containing IL-
12 was performed in TG1 bacterium by LB broth culture 
medium (Merck). The plasmid was extracted by the endo-
free plasmid purification Mega Kit (Qiagen). Then, the OD 
values of the plasmid extraction products were read and 
elution was performed according to the injection of 100 毺g 
to each mouse[7].
2.3. Preparation and injection of IL-22 
  Recombinant IL-22 (rIL-22) protein of murine (Cat. Number 
582-ML; R&D) was prepared according to the manufacturer’s 
protocol. Single doses of rIL-22 5 or 10 ng per g body weight 
(ng/g) in the volume of 100 毺L were injected intramuscular 
before the challenge with promastigotes of L. major[20].
2.4.  Cytokine injection 
  In this study, we divided 60 female BALB/c mice of eight-
week age into six groups of 10 mice. One group of 10 mice 
received PBS (100 毺L) and another group of 10 mice 
received eukaryotic empty plasmid pCAGGS (50 毺g) as 
control groups. Twenty mice received the plasmid encoding 
IL-12 gene (pCAGGS-IL-12) (50 毺g in 100 毺L, eluted 
in PBS), in three doses with three-week intervals. Among 
the mice that received pCAGGS-IL-12, a group of 10 mice 
also received rIL-22 (5 ng/g, IM). The remaining two groups 
received single dose of rIL-22 (5 and 10 ng/g in the volume 
of 100 毺L) in the quadriceps muscle using 30-gauge insulin 
syringes[7, 20].
  Classification of the mice with regard to the treatment they 
received and the follow up. Based on the treatment received, 
mice were divided in 6 groups (n=10 each group) as follow: 
Control groups treated with PBS (100 毺L) and empty 
pCAGGS (100毺g), rIL-22 treated group with 5 ng/g of body 
weight, rIL-22 treated group with 10 ng/g of body weight, 
IL-12 (100 毺g) treated group and IL-12+ IL-22 (100 毺g and 
5 ng/g body weight respectively). All the mice were treated 
intra-muscular (IM) three times with three-week intervals. 
Further each group was divided in two sub-groups of 5 mice 
as follows:
  (1) Seven weeks after applying the above-mentioned 
treatments, the animals were challenged by L. major 
promastigote of the MRHO/IR/75/ER strain and then seven 
weeks later the animals’ humoral and cellular responses 
were measured.
  (2) Seven weeks after applying the treatments, the animals 
were challenged by L. major promastigote of the MRHO/
IR/75/ER strain and then lesion size and weight and survival 
rate of the mice were evaluated.
2.5. Challenge with promastigotes of L. major 
  Seven weeks after the last immunization, the BALB/c mice 
were infected with L. major. The mice were challenged 
with at least 2伊106 L. major promastigotes of the Iranian 
standard strain MRHO/IR/75/ER. The promastigotes were in 
the stationary phase, and were inoculated in the tail base by 
subcutaneous injection (100 毺L). Three to four weeks after 
the injection, a nodule was developed at the injection site, 
and a lesion resulted from the growth of the parasite was 
formed in the tail base[20,21].
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2.6. Evaluation of humoral immunity 
  The humoral immunity was evaluated by measurement of 
total IgG in the sera samples of the immunized and control 
groups using ELISA kits. Furthermore, the antibody subtypes 
(IgG1 and IgG2a) were measured by Mouse Monoclonal 
Antibody Isotyping Reagent Kit (Sigma).
  To determine the antibody levels, optimized volumes of 
the antigen, serum concentration, and conjugated antibody 
concentration were determined using checker board 
titration as previously defined[21]. Then, all sera samples 
were examined by the ELISA method. Then, 100 毺L of the 
crude soluble Leishmania antigen (SLA) at the concentration 
of 20 毺g/mL in the carbonate-bicarbonate buffer was 
prepared. Then, 100 毺L of the sera eluted in PBS buffer 
(1:10) was used.
2.7. Extraction and culture of lymphocytes for cytokine 
evaluation 
  In the mice of sub-group 1, spleen was collected 
and meshed-up to extract the lymphocyte. 2.5伊106/mL
lymphocytes were plated in 24 well tissue culture plate 
with complete RPMI media (Gibco, BRL, Maryland, 
USA) containing 20% FCS (Gibco, BRL, Maryland, USA), 
stimulated with 40ug/ml SLA and cultured at 37 degree, 5% 
CO2 for 72 hours to access the cytokine release. Seventy two 
hours later, the cellular supernatant was collected and kept 
at -70 曟 until cytokine assay[22].
2.8. Cytokine assay 
  INF-毭 and IL-4 levels in the cellular supernatant 
prepared from the spleen lymphocytes of immunized and 
control mice, which were kept at -70 曟, were measured 
by the ELISA method[21], using U-CyTech biosciences 
(Netherlands). According to the standard measures included 
in the kit, the standard diagrams were drawn and the 
samples were evaluated.
2.9. Evaluation of number of parasites in spleen of the mice 
after the challenge 
  Seven weeks after challenge by the parasites, the treated 
and control group mice were sacrificed; the spleens were 
removed under sterile conditions and weighed and large 
volumes of the spleen cellular supernatant was used for 
lymphocyte extraction. Almost 60 毺L of the spleen cellular 
suspension was cultured under sterile condition in 1.5 mL 
microtube containing 1 mL RPMI 1640 (containing 20% 
FCS, 100 unit/mL penicillin, and 100 毺g/mL streptomycin). 
After eight days of incubation at 24-25 曟, the presence 
or absence of mobile promastigotes and the number of 
promastigotes in each ml was microscopically evaluated[21].
2.10. Measurement of lesion size and body weight of mice 
  In subgroup 2, after the challenge and creation of the 
lesion, the lesions size were measured weekly by a digital 
caliper and considered as the lesionsize. To confirm the 
lesion resulted from Leishmania, we obtained samples from 
the lesions. The body weight of mice measured by a digital 
scale weekly. After the parasite challenge, the life span and 
survival rate of the immunized and control mice were weekly 
measured[21].
2.11. Statistical analysis 
  The results were analyzed using SPSS software. In this 
regards, INF-毭, IL-4, MTT, IgG and its subtypes, parasite 
loads in spleen, lesion size and survival rate of mice were 
analyzed. Non-parametric data were compared by Mann-
Whitney test.
3. Results 
3.1. Survival rate 
  In all groups, the survival rate was 100% up to week six. 
Mortality of the control groups started from week seven on 
(week seven: mortality 20%; survival rate 80%).
  Mortality for the IL-12, IL-12+IL22, and IL-22-5 ng/g 
groups started from week 26 and 27.
  The mortality rates for PBS and pCAGGS control groups 
were 100% in weeks 26 and 27 after the challenge with L. 
major. This is while at this point, the survival rates for IL-
12, IL-12+IL-22, and IL-22-5 ng/g groups were 100%. The 
survival rate of 80% for IL-12 and IL-12+IL-22 groups was 
observed at week 28, while this was observed at week 26 for 
the IL-22-5 ng/g group (Figure 1).
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Figure 1. Survival rate of the mice that received IL-12, IL-22, and 
IL-12+IL-22 in comparison with the control groups during the 30 
weeks of evaluation after the challenge with 2×106 promastigotes of L. 
major.
3.2. Body weight of mice 
  The groups that received 5 and 10 ng of rIL-22 were not 
significantly different with regard to the weight of mice. 
However, rIL-22-5 ng/g was significantly different from the 
control groups (pCAGGS and PBS) in this respect (P<0.05) 
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(Figure 2).
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Figure 2. Mean and standard deviation of weight (g) in treated and 
control groups of BALB/c mice at week 7 after the challenge with 2 × 
106 L. major promastigotes.
  Statistically significant differences were observed among 
the IL-12, IL-12+IL-22, and IL-22-5 ng/ggroups (P<0.05). 
The results did not show anysignificant difference between 
IL-12 and IL-12+IL-22 groups in the weight of mice 
(P>0.05).
3.3. Lesion status 
  The mean lesion size in the IL-22-5 ng/g was smaller than 
that in the IL-12 group, and as shown, the differences in 
different weeks of the study were statistically significant 
(P<0.05). 
  Furthermore, the lesion size in IL-12+IL-22 group was 
smaller than that in the IL-12 group. In different weeks of 
the study, both groups were significantly different in this 
respect (P<0.05) (Figure 3).
3.4. IgG total, IgG1 and IgG2 
  In the mice of sub-group 1 the humoral immunity was 
determined. Comparison between mean and SD of IgG total, 
IgG1 and IgG2 in different groups of mice is given in Table 1.
3.5. INF-毭 
  The mean INF-毭 level in the IL-22 (5 ng/g) was 
significantly higher than that in the IL-22 (10 ng/g). Also in 
IL-22 (5 ng/g) group, INF-毭 production was significantly 
higher than other groups.
  The mean level of INF-毭 in the IL-22-10 ng/g was 
significantly different from the levels in the pCAGGS and 
PBS groups (P<0.05). The mean level of INF-毭 in the IL-
22-5 ng/g group was significantly higher than the values 
obtained for other groups (P<0.05) (Table 2).
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Figure 3. The mean and SD of lesion size (mm) in treated and control 
groups of BALB/c mice in three doses with three-week intervals, 7 
weeks after the challenge with 2 × 106 L. major promastigotes.
3.6. IL-4 
  The mean level of IL-4 showed a decreasing trend in the 
groups that received IL-22. These groups were significantly 
different from the other groups.
  In IL-22 group (5 ng/g), IL-4 was significantly lower than 
other groups, whereas the IL-4 for IL-22 (10 ng/g) group was 
significantly lower only with control groups (Table 2).
3.7. Spleen weight and number of parasites in spleen after 
challenge 
  Enlargement of the spleen (as a lymphatic organ) and 
increase in its weight in the control mice are parameters 
indicating the increase in number and accumulation 
of immune cells in the organ. The accumulation could 
demonstrate the presence of the parasite in the spleen or 
exposure of the immune cells with infectious factors.
  The data related to the spleen weight and parasite count 
in week 7 after the challenge by L. major demonstrated 
Table 1
Mean and SD of IgG total, IgG1 and IgG2 in different groupsof mice seven weeks afterchallenge with L. major promastigotes of the MRHO/IR/75/
ER strain.
Group Cytokine regimen
IgG1 IgG2 IgG-total
Meen依SD Sig(P<0.05) Meen依SD Sig(P<0.05) Meen依SD Sig(P<0.05)
1 PBS   0.354 0依0.001 9   3, 4, 5, 6 0.422 0依0.000 8     3, 4, 5, 6 0.417 0依0.000 4     3, 4, 5, 6
2 pCAGGS   0.374 0依0.002 6   3, 4, 5, 6 0.441 0依0.000 5     3, 4, 5, 6 0.424 0依0.000 5     3, 4, 5, 6
3 IL-22 (5 ng/g)   0.732 0依0.001 7 1, 2, 4, 5, 6 0.998 0依0.000 8    1, 2, 5, 6 0.785 0依0.000 7     1, 2, 5, 6
4 IL-22 (10 ng/g)   0.595 0依0.000 6 1, 2, 3 0.916 0依0.000 4 1, 2, 5 0.714 0依0.000 5     1, 2, 5, 6
5 IL-12   0.540 0依0.001 3 1, 2, 3 0.815 0依0.000 5 1, 2, 4 0.582 0依0.000 4     1, 2, 3, 4
6 IL-22 (5 ng/g)+IL-12   0.563 0依0.000 6 1, 2, 3 0.845 0依0.000 1 1, 2, 3 0.594 0依0.000 7     1, 2, 3, 4
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that the control groups were significantly different from the 
experiment groups in this respect (Table 3).
4. Discussion 
  In the current study, for the first time, we evaluated 
the effect of IL-22 together with IL-12 on cutaneous 
leishmaniasis caused by L. major in BALB/c mice. The 
results indicated higher effectiveness of IL-22 in treatment 
of cutaneous leishmaniasis. This is supported by the lowest 
lesion size among the groups in the IL-22-5 ng/g group in 
week seven. Furthermore, mice in the IL-22-5 ng/g group 
had the highest weight and survival rate. 
  The results of INF-毭 and IL-4, evaluations in BALB/
c mice demonstrated that IL-22 evidently increased the 
INF-毭 production and reduced the IL-4 production after 
the challenge. Administration of IL-22 caused a statistically 
significant difference between this group and other groups in 
this respect. This shows that IL-22 resulted in development 
of Th1 cytokine responses and indicates that the cytokine 
is effective in treatment of cutaneous leishmaniasis. Co-
administration of cytokines with other treatments is currently 
performed in treatment of many infectious and parasitic 
diseases to enhance the protective responses of T cell 
subpopulations[7, 18-20, 23-24]. In this study, it was observed 
that IL-22 has a dose-dependent effect; such as 5 ng/g 
produced better responses in comparison with 10 ng/g.
At some doses, IL-22 has synergistic effect with other 
cytokines; for instance, IL-22 at 200 ng/mL together with 
IL-17A (20 ng/mL) is effective in treatment of psoriasis. This 
is caused by activation of S100A8 and S100A9 pathways 
through the synergistic effect of IL-17A and IL-22[25].
  In some studies, long-term and high doses of IL-22 
have been reported to be associated with adverse effects 
and there are some reports on the carcinogenicity of the 
cytokine[25]. However, such reports are not available for the 
permitted doses (2-20 ng/mL).
  There is some evidence indicating that IL-17 and IL-
22 play the complement role in natural immunity against 
Leishmania donovani (L. donovani). This hypothesis 
is consistent with the effect of Th17 on monocytes and 
neutrophils and the ability of Th17 cells in infiltration of 
Th1 cells and formation of granulomas[19]. Furthermore, IL-
17 and 22 hasten tissue regeneration and strengthen the 
epithelial cells; thus, contributing to the immunity and 
protection[25].
  Mean lesion size in the groups that received IL-22 was 
significantly different from that in other groups. The lesion 
size in the group that received IL-12+IL-22 was close to 
the values obtained for IL-22 groups. Therefore, it could be 
probably stated that IL-22 performed better than IL-12 in 
reducing the lesion growth and wound healing in cutaneous 
leishmaniasis. It has been found that skin keratinocytes 
have receptors for IL-22. It was shown in a study that, IL-22 
induces antimicrobial peptidesin skin, enhances proliferation 
of keratinocytes and inhibits their differentiation, and plays a 
role in skin regeneration in innate immunity mechanisms[17]. 
  The protective role of IL-22 against human Kala-azar has 
been reported previously[19]. In our own previous study, we 
found that IL-22 as an adjuvant could show effective role 
in DNA vaccine with plasmid encoded LACK gene against 
cutaneous leishmaniasis[26]. The mean levels of IFN-毭 in 
the groups that received IL-22 were significantly higher 
than those in other groups. This indicates that IL-22 
resulted in development of Th1 cytokine response in mice 
suggesting its protective role in cutaneous leishmaniasis 
specially when used at 5 ng/g concentration.
Table 2
Mean comparison of INF-毭 and IL-4 levels (pg/mL) of the groups after the challenge.
Group Cytokine regimen Mean 依 SD ( IFN - 毭)  Sig(P<0.05)
* (IFN -毭 ) Mean 依 SD ( IL-4) Sig(P<0.05)
 * ( IL-4)
1 PBS 176.25依34.49  3, 4, 5, 6 203.75依14.34 3, 4, 5, 6
2 pCAGGS 123.75依20.56  3, 4, 5, 6 229.75依33.67 3, 4, 5, 6 
3 IL-22 (5 ng/g) 1744.50依157.95  1, 2, 4, 5, 6   3.75依4.50 1, 2, 4, 5, 6 
4 IL-22 (10 ng/g) 271.25依41.82 1, 2, 3, 6 14.25依5.12 1, 2, 3
5 IL-12 441.75依89.41 1, 2, 3 15.50依3.70 1, 2, 3
6 IL-22 (5 ng/g)+IL-12   632.25依168.35 1, 2, 3, 4 12.25依3.69 1, 2, 3
 * indicates significance (P<0.05) according to the Mann Whitney test.
Table 3
Mean and standard deviation of spleen weight (g) and parasite count in week 7 after the challenge.
Group Cytokine regimen Spleen weight(g) Parasite in spleen× 105
1 PBS 0.890依0.017 13.85依0.25
2 pCAGGS 0.840依0.015 14.11依0.22
3 IL-22 (5 ng/g) 0.300依0.002 -
4 IL-22 (10 ng/g) 0.320依0.002 -
5 IL-12 0.360依0.062 2.26依0.09
6 IL-22 (5 ng/g)+IL-12 0.760依0.022 1.90依0.11
Data were expressed as Mean 依 SD. 
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